Navigation Links
DURECT Provides an Update to the Memryte Program Under Development,by Voyager Pharmaceutical Corp

CUPERTINO, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- DURECT Corporation announced today that Voyager Pharmaceutical has provided its shareholders with an update on its truncated Phase 3 clinical trial for Memryte, an investigational drug for the treatment of Alzheimer's disease. Voyager has informed its shareholders that they have observed positive outcome trends among women, but no positive effect among men. DURECT has not independently verified the analysis performed or conclusions of Voyager. Based on these results, Voyager has stated that it intends to focus its efforts on developing Memryte for the treatment of Alzheimer's disease in women and on seeking a potential partner for the program.

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company developing pharmaceutical systems based on its proprietary drug delivery platform technologies. The Company currently has a number of late-stage pharmaceutical products in development addressing large markets in pain management, with a number of research programs underway targeting chronic disease and other therapeutic areas. For more information, please visit www.durect.com.

Forward-Looking Statement

The statements in this press release regarding Memryte, its potential performance and attributes, future development plans for Memryte and efforts by Voyager to seek a partner for the program are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Voyager's abilities to attract and reach business terms with a partner for the Memryte program, design, enroll, conduct and complete clinical trials, obtain successful results from such clinical trials, complete the design, developme nt, and manufacturing process development of Memryte, obtain regulatory and manufacturing approvals from regulatory agencies, and manufacture and commercialize Memryte, as well as marketplace acceptance of Memryte. Further information regarding these and other risks is included in DURECT's Form 10-Q dated May 9, 2007 under the heading "Risk Factors."

NOTE: Memryte is under development and has not been submitted or approved for commercialization by the US Food and Drug Administration or other health authorities.

CONTACT: Jeremiah Hall, Senior Vice President of Feinstein KeanHealthcare, +1-415-677-2700, or jeremiah.hall@fkhealth.com

Web site: http://www.durect.com//

Ticker Symbol: (NASDAQ-NMS:DRRX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
8. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
9. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
10. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
11. NeoPharm Provides Update on LE-SN38 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- Brain Cancer patients in the Mid-South ... West Cancer Center . Optune™, a portable ... cell replication causing death of cancer cells, is the ... show a significant extension in overall survival rates for ... Cancer Center is the only medical center in ...
(Date:2/11/2016)... 2016  AbbVie, a global biopharmaceutical company, announced ... to provide financial support for exceptional students living ... education goals. Fifteen scholars will be selected to ... The AbbVie Rheumatology Scholarship is currently accepting applications. ... corporate social responsibility, brand and communications, AbbVie. "By ...
(Date:2/11/2016)... , Feb. 11, 2016 PLAD, Inc. ... out 2016 with sales exceeding company targets, are adding ... received their trademark from the United States Patent and ... Clark , Chief Executive Officer of PLAD, Inc.  In ... Pennsylvania with two new customers, ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases ... evaluation of DataPoint’s team dedication and commitment to the SharePoint ecosystem. A ... annual list. The panel’s goal is to recognize and promote technology entrepreneurship. , ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Be ... new office in the heart of Old Town at 108 South Columbus St, Suite ... businesses the highest level of medical care in the convenience of their homes, offices ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hoggan ... force gauges used in physical therapy, occupational therapy and sports medicine clinics, hospitals, ... cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. , ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... become more actively engaged in health and wellness best practices in the past ... riding this trend. February is American Heart Month, which acts as an exceptional ...
(Date:2/11/2016)... ... February 11, 2016 , ... Research led by Providence ... several common cancer screenings, especially among women. Cancer screenings are often the best ... , The study,“What Does Medicaid Expansion Mean for Cancer Screening and Prevention: Results ...
Breaking Medicine News(10 mins):